Navigation Links
Upsher-Smith To Present New Research On USL255 (Extended-Release Topiramate) At 2013 American Epilepsy Society Annual Meeting
Date:11/18/2013

MAPLE GROVE, Minn., Nov. 18, 2013 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. (Upsher-Smith), today announced that it will present new research from its epilepsy clinical development program for USL255 (extended-release topiramate) during the American Epilepsy Society's (AES) 67th Annual Meeting in Washington, DC, December 6-10, 2013.  

(Logo:  http://photos.prnewswire.com/prnh/20130520/NY17281LOGO)

Seven presentations will highlight results from the PREVAIL clinical trial, the first of its kind conducted on an extended-release formulation of topiramate.  The global Phase 3 study enrolled more than 200 patients and assessed the efficacy and safety of USL255 as an adjunctive treatment of epilepsy in patients with refractory partial-onset seizures (POS).  In addition, two presentations will feature Phase 1 findings including the pharmacokinetics of USL255 when sprinkled onto food or swallowed intact and the impact of delayed-dose administration of USL255.

USL255 is a once-daily, broad-spectrum antiepileptic drug specifically engineered to deliver a smooth pharmacokinetic profile.  It is being developed by Upsher-Smith for the management of seizure disorders.  Upsher-Smith's New Drug Application for USL255 has been accepted for review by the U.S. Food and Drug Administration (FDA).

"This year's AES meeting marks the first time the findings from our Phase 3 trial will be presented publicly," said William Pullman, MB BS, BMedSc, PhD, FRACP, Chief Scientific Officer, Upsher-Smith.  "We look forward to sharing data from the first global Phase 3 clinical trial of an extended-release formulation of topiramate with the epilepsy community at this year's Annual Meeting." 

Poster Presentations

PREVAIL Phase 3 Clinical Trial

USL255 Phase 1

Abstracts of the poster presentations can be found online at www.aesnet.org.  To schedule an interview with an investigator, please contact Elizabeth Likly at elikly@klcpr.com.  

About Upsher-Smith's Phase 3 (PREVAIL) Clinical Trial

The PREVAIL trial was a randomized, multicenter, double-blind, placebo-controlled, parallel-group study designed to evaluate the efficacy and safety of USL255 as adjunctive therapy in patients with refractory POS. 

PREVAIL was conducted under a Special Protocol Assessment (SPA) agreement with the FDA.  More information about the trial is available at www.clinicaltrials.gov (NCT01142193).

An open-label extension study to evaluate the safety of USL255 as adjunctive therapy in patients with refractory POS who had participated in PREVAIL is ongoing.  The open-label extension study can be found by searching NCT01191086 on www.clinicaltrials.gov.

Upsher-Smith's Epilepsy Pipeline

Upsher-Smith's clinical development pipeline includes three investigational drugs that are being studied for the management of seizure disorders.  USL255 is an investigational once-daily, extended-release topiramate for the management of epilepsy.  The pipeline also includes USL261, an investigational intranasal midazolam for the rescue treatment of seizures in patients who require control of intermittent bouts of increased seizure activity, often called seizure clusters, which is the subject of an ongoing international Phase 3 clinical trial (ARTEMIS1) with an open-label safety extension study.  In addition, USL260 (tonabersat) is in early clinical development as a potential first-in-class neuronal gap junction modulator.

About Upsher-Smith

Upsher-Smith, founded in 1919, is an independent and privately-owned specialty pharmaceutical company headquartered in Maple Grove, Minnesota that focuses on product growth and innovation for branded and generic pharmaceuticals.  Upsher-Smith has a particular focus on developing therapies to assist people suffering from central nervous system diseases and also markets products relating to cardiology, dermatology, and women's health.  For more information, visit www.upsher-smith.com.

 


'/>"/>
SOURCE Upsher-Smith Laboratories, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Upsher-Smith Research Shows Unique Pharmacokinetic Profile of USL255 Extended Release Topiramate
2. Dave Zitnak Of Upsher-Smith Laboratories Named Branded Representative Of The Year By McKesson Corporation
3. Upsher-Smith Is Honored with Prestigious Industry Award for Excellence and Innovation
4. Upsher-Smith Teams Up With Epilepsy Foundation of Minnesota for 2012 Stroll for Epilepsy
5. Tina Fehr, Senior Product Manager For AmLactin, Upsher-Smith Laboratories Named PM360 Trailblazer Winner For Womens Health Brand Manager
6. Doug Zitnak of Upsher-Smith Laboratories Named Small Brand Manufacturer Representative of the Year By Cardinal Health
7. Emerging Data From Upsher-Smiths CNS Portfolio Highlighted At 2013 American Academy Of Neurology Meeting
8. Upsher-Smith Presents Data Supporting Favorable Tolerability And Consistent Pharmacokinetic Profile Of Once-Daily USL255 (Extended-Release Topiramate)
9. Upsher-Smith Introduces Newly Redesigned Corporate Website
10. Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures
11. Upsher-Smith Is Honored With Prestigious Industry Award For Leadership And Innovation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... PUNE, India , February 10, 2016 ... to a new market research report "Pharmaceutical Packaging Equipment ... Packaging, Wrapping, Labeling & Serialization), by Product Type (Tablet, ... to 2020", published by MarketsandMarkets, studies the global market during ... is expected to grow at a CAGR of 6.9% ...
(Date:2/10/2016)... February 10, 2016 ... Targeted Therapeutics and Companion Diagnostic Market to 2019 ... and Environment" research report indicates that the core ... billion by 2020 growing at a CAGR of ... diagnostics and targeted therapeutics and is dominated by ...
(Date:2/9/2016)...  Misonix, Inc. (NASDAQ: MSON ), an ... markets innovative therapeutic ultrasonic products for spine surgery, ... surgery and other surgical applications, today announced financial ... half of fiscal year 2016 ended December 31, ... --> Highlights for the second quarter and ...
Breaking Medicine Technology:
(Date:2/10/2016)... Denver, Colorado (PRWEB) , ... February 10, 2016 , ... ... now, but cannabis enthusiasts in the state still face a lot of restrictions as ... “retail marijuana is intended for private, personal use” and that cannabis “may not be ...
(Date:2/10/2016)... (PRWEB) , ... February 09, 2016 , ... A new ... for Summer 2016. FHU President Joe Wiley made the announcement Monday night, Feb. 8, ... Montague, a 2003 graduate of FHU and the creator of GO! Camp, has been ...
(Date:2/10/2016)... FLA (PRWEB) , ... February 09, 2016 , ... ... team at Clevens Face and Body Specialists are delighted to welcome a new ... ARNP joins Clevens Face and Body Specialists as a nurse practitioner performing ...
(Date:2/10/2016)... Franklin, TN (PRWEB) , ... February 09, 2016 ... ... related to sports concussion, yet the cause of injury may be one of ... This two-day advanced PT Continuing Education Course , Mastering Rehab Solutions ...
(Date:2/9/2016)... (PRWEB) , ... February 09, 2016 , ... Steven Douglas ... Taste of South Florida Event, an upscale fundraiser held in South Florida. The Inaugural ... and guests alike. This year the event will be held in a new, more ...
Breaking Medicine News(10 mins):